Barclays Initiates Coverage On TransMedics Group with Overweight Rating, Announces Price Target of $120

Benzinga Newsdesk www.benzinga.com Neutral 50.8%

Neg 0% Neu 50.8% Pos 0%

Barclays analyst Christopher Pasquale initiates coverage on TransMedics Group (NASDAQ:TMDX) with a Overweight rating and announces Price Target of $120.